NCT01911546View on ClinicalTrials.gov

Role of Everolimus in Highly Sensitized Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 19, 2016

Conditions
Highly-sensitized Kidney Transplant Recipients
Interventions
DRUG

everolimus + low-dose tacrolimus

Patients are supplied everolimus (Zortress) + prograf

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Joseph Kahwaji, MD, MPH

OTHER